NEXT GENERATION GLP PEPTIDE IN
FDA
APPROVAL
IN PARTNERSHIP WITH SYRACUSE UNIVERSITY
GLUCAPHARM INC., 100%-OWNED SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE: SURE, OTCQB:SURNF) IS ADVANCING SYRACUSE UNIVERSITY’S GEP-44, A NEXT-GENERATION GLP FORMULATION (SIMILAR IN FUNCTION TO OZEMPIC®, WEGOVY®, MOUNJARO®, BUT WITH REDUCED RISK OF ADVERSE EVENTS) TOWARDS FDA APPROVAL AND COMMERCIALIZATION WITHIN ONE OF THIS GENERATION’S HIGHEST REVENUE GENERATING PHARMACEUTICAL SEGMENTS FOR OBESITY, DIABETES AND CARDIAC DISEASE
DISCLAIMER – Forward Looking Information and Statements
This presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward looking statements. Forward looking information is often, but not always, identified by the use of words such as “could”, “should”, “can”, “anticipate”, “expect”, “believe”, “will”, “may”, “projected”, “sustain”, “continues”, “strategy”, “potential”, “projects”, “grow”, “take advantage”, “estimate”, “well positioned” or similar words suggesting future outcomes. In particular, this presentation contains forward looking statements relating to future opportunities, business strategies and objectives and management plans, competitive advantages, the expected financial performance of the Surenano Science Ltd. and Glucapharm Inc. (“Surenano”, “Glucapharm”, the “Corporation”, “Company” or the “Corporations”, “Companies”).
The forward-looking statements regarding the Corporation are based on certain key expectations and assumptions of the Corporation concerning anticipated financial performance, business prospects, strategies, tax laws, the sufficiency of budgeted capital expenditures in carrying out planned activities, the availability and cost of labour and services and the ability to obtain financing on acceptable terms, all of which are subject to change based on market conditions and potential timing delays. Although management of the Corporation consider these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect.
By their very nature, forward looking statements involve inherent risks and uncertainties (both general and specific) and risks that forward looking statements will not be achieved. Undue reliance should not be placed on forward looking statements, as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in the forward looking statements, including among other things: liabilities and risks; general economic and market factors, including business competition, changes in government regulations or in tax laws; general political and social uncertainties; lack of insurance; delay or failure to receive board or regulatory approvals; changes in legislation affecting the Corporation; timing and availability of external financing on acceptable terms; and lack of qualified, skilled labour or loss of key individuals.
Readers are cautioned that the foregoing list is not exhaustive.
The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this presentation are made as of the date hereof and the Corporation does not undertake and is not obligated to publicly update such forwardlooking statements to reflect new information, subsequent events or otherwise unless so required by applicable securities laws.
Prospective Investors Should Consult with their Advisors.
The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation.
All amounts are expressed in Canadian dollars unless otherwise noted.
GLUCAPHARM INC., SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE:SURE, OTCQB: SURNF) IS DEVELOPING A NEXTGENERATION GLUCAGON-LIKE PEPTIDE (“GLP") GEP-44 IN PARTNERSHIP WITH SYRACUSE UNIVERSITY DESIGNED TO ADDRESS OBESITY AND METABOLIC DISEASE
GLUCAPHARM’S NEXT-GENERATION GLP SOLUTION, GEP-44,
IS A NOVEL, PATENTED PEPTIDE DEVELOPED AT SYRACUSE
UNIVERSITY, THAT TARGETS LIMITATIONS SUCH AS GASTROINTESTINAL SIDE EFFECTS INCLUDING NAUSEA, NEEDLE INJECTION BURDEN, AND LONG-TERM ADHERENCE ISSUES THAT CURRENT MARKET LEADERS (OZEMPIC®, WEGOVY®, MOUNJARO®) FACE
OBESITY TO HIT $2 BILLION BY 2034 IN 7 MAJOR MARKETS, WHO REPORTS GLOBAL PREVALENCE RATE OF 1 IN 127 INDIVIDUALS
The GLP-1 drug market is experiencing massive growth, with sales driven by high demand for obesity and diabetes treatments like Ozempic®, Wegovy®, and Zepbound®, which are reshaping the pharmaceutical landscape
BY 2030, AN ESTIMATED ~1 BILLION PEOPLE COULD BE OBESE, FUELLING DEMAND FOR EFFECTIVE PHARMACOLOGICAL TREATMENTS
GLOBAL GLP-1 MARKET CONTINUES ROBUST GROWTH DUE TO RISING TYPE 2 DIABETES AND OBESITY PREVALENCE WORLDWIDE. THE OVERALL GLP-1 THERAPEUTIC MARKET WAS VALUED AT ~$24 BILLION IN 2026, PROJECTED TO REACH ~$33 BILLION BY 2030
OVERALL OBESITY TREATMENT MARKET (INCLUDING ALL THERAPEUTICS) WAS VALUED AT ~$15.9 BILLION IN 2024, FORECAST TO GROW TO +$60 BILLION BY 2030
GROWING OPPORTUNITY
EXECUTIVE SUMMARY – Microcap Investment Opportunity Build A Next-Generation GLP
๏ RARE INVESTMENT OPPORTUNITY IN A MICROCAP,
NEXT-GENERATION GLP PEPTIDE
THERAPEUTICS COMPANY WITH GLP PORTFOLIO SIMILAR TO BIG PHARMA (LINK): A combination that creates a differentiated, publicly listed metabolic disease portfolio with Syracuse University’s patented GEP-44 drug innovative and advanced delivery technologies
๏ OPPORTUNITY: Obesity and type 2 diabetes represent one of the largest and fastest-growing global healthcare markets. GLP-based therapies are redefining metabolic care, with a projected market exceeding US$400 billion over the next decade
๏ LEAD, PATENTED ASSET: Discovered and developed by Dr. Robert Doyle and Syracuse University, GEP-44 is a novel, monomeric peptide multi-agonist that targets the GLP-1 and NPY receptors
๏ PRECLINICAL EFFICACY AS TOP CONTENDER: Preclinical studies have demonstrated its equivalent efficacy to Ozempic® in achieving weight loss and glucose control, with the added benefit of improved tolerability. Syracuse University work funding has been provided by the National Institute of Health (NIH) and other USA entities
PATENTED GEP-44 DEVELOPED THROUGH AND ROLLED OUT OF UNIVERSITY RESEARCH
GEP-44 IS A MONOMERIC PEPTIDE THAT ACTS AS A TRIPLE AGONIST ON GLP-1 AND PEPTIDE YY (PYY) RECEPTORS Y1 AND Y2, COMBINING THE BENEFITS OF GLP-1 AND NPY SIGNALLING PATHWAYS
THERAPEUTIC MECHANISM
-GLP-1R activation → glucose control, insulin release
-Y2-R activation → appetite suppression (reduced food intake)
-Y1-R activation → reduced nausea and vomiting, enhanced muscle glucose uptake
SCIENTIFIC CORE
SUPERIOR EFFICACY & TOLERABILITY OVER EXISTING GLP-1 DRUGS (OZEMPIC®, WEGOVY®, MOUNJARO® ETC.)
PRECLINICAL
DATA: In obese rat studies, GEP-44 achieved 15% weight loss vs. 9% for liraglutide, with 39% lower food intake compared to 20% for liraglutide
NO GASTROINTESTINAL SIDE EFFECTS: No nausea or vomiting observed (even in shrew models), a critical differentiator since GI events account for >40% of adverse effects in current GLP-1RA drugs
SHORTACTING BENEFIT: Rapid offset allows flexible dosing and reduced risk of gastric paralysis or malaise
GLUCAPHARM’S GEP-44 VALUE PROPOSITION
๏ PROPRIETARY GEP-44 SOLUTION: A patent-protected, triple-agonist peptide targeting the GLP-1 receptor, Neuropeptide Y1 receptor and Neuropeptide Y2 receptor
๏ NEXT GENERATION PEPTIDE COMPOUND: Addresses common metabolic diseases, GEP-44 offers the potential to outperform current in-market solutions with reduced negative side effects and a differentiated administration method
๏ DISCOVERED AT : Extensive NIH and U.S. Department of Defense-backed research funding received by Syracuse University, partially used in development of GEP-44
๏ STRONG PRECLINICAL DATA: Ozempic®-level or superior weight loss and glucose control, including significantly reduced nausea and GI side effects, including cardiovascular, neuroprotective, and anti-inflammatory benefits
GLUCAPHARM’S GEP-44 VALUE
PROPOSITION
๏ DEVELOPING NON-INJECTABLE DELIVERY (ORAL, NASAL OR SUBLINGUAL): Expanding patient adoption and long-term market penetration
๏ COMPETITIVE POSITIONING: Next-generation GLP solution vs first-and second-generation incumbents. Differentiation based on (1) Triple-agonist mechanism, (2) Superior tolerability profile, (3) Potential needle-free delivery, (4) Positioned as a best-in-class or first-in-class metabolic peptide
๏ PATH FORWARD WITH MULTIPLE CATALYSTS - IND-
ENABLING FDA STUDY: Collaboration with experienced Australian contract research organization (CRO), with IND-enabling FDA study followed by Phase I Clinical Trial expected to commence in Australia; development milestones anticipated over next 6-9 months including IND progression and early clinical validation
๏ LONG TERM OPTIONALITY: Obesity, diabetes, cardiovascular, and neurological indications
SCIENCE: GEP-44 is part of a series of chimeric peptides designed to target 2 key receptors
๏ Neuropeptide Y-receptor (Y2-R) to reduce food intake (FI), and GLP1-R to improve glucose regulation
๏ In preclinical studies (male and female rats), GEP-44 has shown a significant reduction in foot intake (12-65%), improved glucose tolerance and protection of beta-islet cells against inflammatory damage while providing cardio and neuro protection
๏ Chimeric Peptide (GEP-44) reduces body weight, both energy intake and energy expenditure in diet-induced obese rats
๏ Findings suggest that GEP44 and related peptides may offer a safe and
e
ffective treatment option for obesity and type 2 diabetes
KEY BENEFITS: Favourable profile, lacking the nausea, vomiting, and malaise commonly associated with other GLP-1 agonists
๏ Improved weight loss and glucose control
๏ Protection of beta-islet cells against inflammatory damage, thereby protecting against the exacerbation of obesity and diabetic pathophysiology
๏ Superior Weight Loss and Glucose Control
๏ Enhanced Tolerability compared to existing GLP-1 agonists (e.g., Ozempic)
๏ Preservation of β-Cell Mass and Protection of β-islet cells from inflammation
๏ Reduced Gastrointestinal Side Effects and minimal malaise
๏ Potential secondary benefits including cardiovascular support and potential aid in reducing opioid addiction and withdrawal symptoms
AGONIST
GEP-44
FDA PATHWAY – Accelerated Development Timeline to FDA Approval
2025
PRECLINICAL STUDIES
DEMONSTRATING EFFICACY AND TOLERABILITY
Demonstrates equivalent efficacy to Ozempic in achieving weight loss and glucose control, with the added benefit of improved tolerability
2025
DATA READY FOR INDENABLING GLP STUDIES
Paving the way for clinical trials
6 MONTHS
Q2-2026
CONDUCT GMP-CERTIFIED MANUFACTURING OF GEP-44
While maintaining CMC, potentially with GenScript
Q3-2032
REGULATORY DRUG APPROVAL
Obtain approval from regulatory authorities, paving the way for commercialization and patient access
2025
PATENT PROTECTED (IP)
Monomeric peptide multi-agonist targeting the GLP-1 receptor and NPY receptors (US Patent Application 20220204581A1);
Patent protection until 2042: LINK
Q1-2026
IND-ENABLING STUDIES & COLLABORATION WITH AUSTRALIAN CRO
Conduct GLP-certified Toxicology and Pharmacology studies to support regulatory submissions for clinical trials
12 MONTHS
Q3-2027- Q2-2032
CLINICAL TRIALS PHASE I-III
Initiate Phase I-III clinical trials to evaluate the safety and efficacy of GEP44 in humans (12-24 months)
MARKET COMPARABLES – Redefining
PRECLINICAL EFFICACY IN NEXT-GENERATION GEP-44 HAS THE POTENTIAL TO COMPETE WITH COMPOUNDS DEVELOPED AS OZEMPIC®, MOUNJARO®, WEGOVY®
OZEMPIC® - NOVO NORDISK
US$220 BILLION
MC
-Semaglutide - Approved for type 2 diabetes; weight‐loss use is off-label, GLP-1 receptor agonist (once weekly injection)
-Established diabetes indication, weight loss benefit known, but at lower doses compared to obesity‐specific drugs
WEGOVY® - NOVO NORDISK
US$220
BILLION MC
-Semaglutide - Approved for chronic weight management (obesity), GLP-1 receptor agonist at higher dose
-Design specific to weight‐management, same mechanism as Ozempic, different dose/formulation, obesity/metabolic disease commercial go-to
MOUNJARO® - ELI LILLY
US$990 BILLION MC
-Tirzepatide - Approved for type 2 diabetes; also being used (and expected) for weight-loss / obesity indication
-Dual agonist: GIP + GLP-1 receptor agonist; Mechanistically more “advanced” (dual hormone pathway) compared to a pure GLP-1; greater weight‐loss in trials
VALUE CREATION FOR SHAREHOLDERS
๏ VERTICALLY INTEGRATED METABOLIC THERAPEUTICS COMPANY:
GlucaPharm contributes a high-value, late-preclinical drug portfolio, GEP-44, public market infrastructure and execution capability
๏ SURENANO AND GLUCAPHARM CREATE A SCALABLE, INVESTABLE
STRUCTURE CAPABLE OF SUPPORTING FDA CLINICAL
DEVELOPMENT AND SUBSEQUENT PARTNERSHIP WITH BIG
PHARMA: As GEP-44 progresses through IND, Phase I, and Phase II-III development towards FDA approval, SureNano will be positioned as one of the only micro-cap public companies developing GLP technology with direct exposure to the multi-hundred-billion-dollar GLP-1 metabolic market, and the potential to compete alongside large pharmaceutical incumbents, and eventual sale/partnership once FDA pathway is further achieved
MANAGEMENT – Led by Experienced Scientific and Capital Markets Executives
Charles MaLette
James Bordian
Chief Executive Officer, President and Director
Chief Financial Officer and Director
Dr. Robert Doyle
Dr. Nihar Pandey
Dr. Peter Billing
Inventor and Advisor
Chief Scientific Officer
Charles MaLette was previously an Investment Advisor for more than 35 years with Canaccord Genuity Corp., with many years investing, fi nancing, analyzing and reviewing public companies in various industries. Mr. MaLette has been the CEO, President and a Director of Stevens Gold since 2018. Graduated from the University of Calgary with a degree in Economics, and completed a teaching degree from the University of British Columbia. Mr. MaLette joined Canaccord Genuity Corp. in 1983 as an Investment Advisor and resigned to become the CEO and director of Core Process Solutions Inc.
James Bordian is a retired Chartered Accountant and Certi fi ed Internal Auditor with over 40 years experience . Held senior management positions with US Plywood, Dillingham Corporation, Air Canada, and BC Hydro. Extensive experience in income tax planning, budgeting, financial statement presentations and business valuations.
Dr. Robert Doyle is a medicinal chemist focused on drug development for obesity and type 2 diabetes, specialized in peptide and protein design, recombinant expression, bioconjugate chemistry, drug delivery, and assay development. He joined Syracuse University in 2005 as Assistant Professor of Chemistry, was promoted to Associate Professor with tenure in 2009, Full Professor in 2014, and named the Laura J. and L. Douglas Meredith Professor in 2016 and Dean’s Professor of Chemistry in 2022. Holds appointments as Associate Professor of Medicine and Pharmacology at SUNY Upstate Medical University.
Dr. Nihar Pandey is a biochemist and clinical researcher with +25 years of experience in drug discovery, development, and regulatory strategy. Developed 7 IP-protected drug formulations, holds five active patents, and has published +35 peer-reviewed papers and 2 book chapters. Chief Scientific Officer at CliniCan Health Research and Paws Pharma. Ph.D. in Clinical Biochemistry and postdoctoral training at Université de Montréal, Clinical Research Institute of Montreal, and McGill University. He held roles at University of Ottawa Heart Institute, Liponex Inc., and worked with Health Canada in regulatory toxicology.
Obesity Expert and Advisor
Dr. Billing is a Mayo-trained metabolic bariatric surgeon, entrepreneur and clinical investigator. Graduated from the University of Minnesota Medical School, Dr. Billing serves as a courtesy medical staff member at Swedish First Hill and holds various leadership roles, including Medical Director at Transform SurgiCenter and Transform Weight Loss LLC. Robust publication record, including research on surgical treatments and bariatric procedures, involved in several clinical trials related to obesity management. Received multiple honors, such as being named a Top Doctor by Castle Connolly in 2023.
Tara Asfour is a capital markets executive with over 12 years of experience in investor relations, fundraising, business development, and corporate communications across primarily resource and technology sectors. She has held senior roles in business development and investor relations, leading more than US$550 million in fundraising and strategic initiatives, as well as US$250 million in fi nancial guarantee products and multiple commodity offtake agreements. Ms. Asfour holds an MBA from Herzing University, executive certificates from Yale and HBS, governance certification from IGOPP.
Tara Asfour Corporate Development
CAP TABLE (*25/02/2026)
1,500,000
APPENDIX
SURENANO SCIENCE LTD. OVERVIEW
๏ SURENANO’S FOCUS ON NANOTECHNOLOGY AND ADVANCED MATERIAL
SCIENCE APPLICATIONS IN HEALTH AND WELLNESS TRANSFORMS A SINGLE ASSET INTO A PLATFORM OPPORTUNITY WITH THE INTEGRATION OF GLUCAPHARM’S GEP-44
๏ SURENANO’S PLATFORM EXPERTISE: Includes novel formulation technologies, drug delivery enhancement, translational development from lab to commercial scale
๏ TRACK RECORD - SURENANOTM PRODUCT LAUNCHED BY EMERALD
SCIENTIFIC IN 2020: 2 years of development with Activated Nano, approved by FDA and Health Canada. SureNano EmulsifierTM compounds are based on 100% plantderived stabilizing formulas that contain everything needed to produce high performance hemp and cannabis nanoemulsions
๏ DELIVERY TECHNOLOGY SYNERGY: SureNano’s nanotechnology and formulation expertise aligns directly with oral, sublingual or nasal peptide delivery, enhanced bioavailability and patient compliance, strengthening GlucaPharm’s differentiation versus injectable-only GLP competitors
๏ IMMEDIATE ENHANCEMENT OF SURENANO’S ASSET PORTFOLIO WITH A GLOBALLY RELEVANT THERAPEUTIC CANDIDATE
